% Expired Patents = 20.0

EPO Patents = 5

Forward Citations = 21

Loading Chart...

19 inventors (with patents filed for the assignee):

Maria Halasz (2 out of 3 patents)

Darren Jones (2 out of 3 patents)

Takashi Muramatsu (2 out of 20 patents)

4. Takashi Matsui (1 out of 112 patents)

5. Akio Suzumura (1 out of 9 patents)

6. Nico Mertens (1 out of 1 patent)

7. Phillip Cunnah (1 out of 1 patent)

8. Shin Miyakawa (1 out of 7 patents)

9. Yoshikazu Nakamura (1 out of 14 patents)

10. Sadatosi Sakuma (1 out of 1 patent)

11. Kenji Kadomatsu (1 out of 12 patents)

12. Sadatoshi Sakuma (1 out of 15 patents)

13. Mitsuru Horiba (1 out of 4 patents)

14. Itsuo Kodama (1 out of 2 patents)

15. Kazuhiko Inoh (1 out of 2 patents)

5 patents: Sort by Forward Citations

1. 10590192 - Midkine antibody (2020-03-17),

2. 9624294 - Antibody recognizing N-domain of midkine (2017-04-18),

3. 9023799 - Method to reduce loss of cardiac function following ischemia/reperfusion (2015-05-05),

4. 8221758 - Anti-midkine antibody for preventing post-laparotomy adhesions (2012-07-17),

5. 8128934 - Method for treatment or prevention of disease associated with functional disorder of regulatory T cell (2012-03-06),

Cellmid Limited is an Australian biotechnology company focused on the development and commercialization of innovative therapies and products for age-related diseases. The company's lead product is evolis, a hair growth technology using FGF5 inhibitor. Cellmid also has a portfolio of midkine-related intellectual property and diagnostic technologies.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

5 Patents

#45 in

#796 in Australia

AU

Cellmid Limited